Long-term efficacy of pegylated recombinant human megakaryocyte growth and development factor in therapy of aplastic anemia.
Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) potently stimulates platelet production in humans, mitigates thrombocytopenia associated with nonmyeloablative chemotherapy, and reduces the need for platelet transfusions. Its long-term effect in patients, however, is not well understood. We report a patient with aplastic anaemia who received 3 cycles of PEG-rHuMGDF 3 times a week for up to 2 years. Platelet counts slightly increased 1 week after the initiation of PEG-rHuMGDF therapy, bleeding episodes decreased, and there was no need for platelet transfusion. Administration of PEG-rHuMGDF increased not only platelet numbers but also reticulocyte counts, and reduced the need for erythrocyte transfusions as well. There were no significant adverse events, and no neutralizing antibodies were detected in the patient.
Yonemura
Yuji
Y
Blood Transfusion Service, Kumamoto University School of Medicine, Japan. yuyone@gpo.kumamoto-u.ac.jp
Miyake
Hirosada
H
Asou
Norio
N
Mitsuya
Hiroaki
H
D000328:Adult; D000741:Anemia, Aplastic / Q000097:blood / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D010976:Platelet Count; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D017701:Reticulocyte Count; D013926:Thrombopoietin / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D011994:Recombinant Proteins; C103117:polyethylene glycol-recombinant human megakaryocyte growth and development factor; D011092:Polyethylene Glycols; D013926:Thrombopoietin